Surveillance and Epidemiology of Drug-resistant Infections Consortium
The Surveillance and Epidemiology of Drug-resistant Infections Consortium (SEDRIC) brings together a range of international experts to share expertise and take action to tackle the gaps in drug-resistant infection surveillance and epidemiology.
On this page
What is SEDRIC?
SEDRIC aims to transform the way countries are able to track, share and analyse information about the rise and spread of drug-resistant infections.
Better information will speed up action and improve public health interventions, saving many lives in the process.
- identify the critical gaps in, and barriers to, the surveillance and epidemiology of drug-resistant infections, and how these can be overcome at a national and global level
- provide technical expertise and knowledge to strengthen and support existing surveillance networks and activities
- improve global co-ordination by helping countries adopt common and sustainable best practices and strategies, that will reduce the impact of drug-resistant infections
- inform and shape Wellcome’s strategy for limiting the future impact of drug-resistant infections.
The SEDRIC board has 12 members, with expertise spanning genetics, epidemiology, microbiology, public health and animal health. The current chair is Professor Sharon Peacock.
The board will commission reviews and convene fixed-term working groups to address key issues in the fight against drug-resistant infection. This could include how to develop guidelines and tools to encourage data sharing, or how to translate scientific evidence into policy.
It began its work in January 2018 and is funded by Wellcome.
Global intelligence on superbugs vital to stop antibiotic resistance
Professor Sharon Peacock, the board’s chair, explains why SEDRIC is necessary and what it aims to do. Read her article.
- Find out more about our drug-resistant infection priority area.